Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nolato ABFRA:NBF +1.96%74 Debt-to-Equity is 0.00 as of Jun. 2026. GuruFocus rates FRA:NBF with a GF Score™ of 74/100 and a GF Value™ of €4.64 (Fairly Valued). The stock has 3 warning signs investors should review. Among 697 Medical Devices & Instruments companies, Nolato AB ranks worse than 52.22% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Nolato AB's Debt-to-Equity or its related term are showing as below:
FRA:NBF'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.09 Med: 0.34 Max: 0.51
Current: 0.26
During the past 13 years, the highest Debt-to-Equity Ratio of Nolato AB was 0.51. The lowest was 0.09. And the median was 0.34.
FRA:NBF's Debt-to-Equity is ranked worse than 52.22% of 697
companies
in the Medical Devices & Instruments industry
Industry Median: 0.23
vs FRA:NBF: 0.26
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Nolato AB Debt-to-Equity Related Terms
Nolato AB Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Nolato AB's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:NBF vs ABT, SYK, MDT: Debt-to-Equity Comparison
For the Medical Devices subindustry, Nolato AB's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nolato AB Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nolato AB's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Nolato AB's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nolato AB (FRA:NBF) has a Debt-to-Equity of 0.00 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Nolato AB and its competitors. Over the past decade, Nolato AB's Debt-to-Equity has ranged from 0.09 to 0.51. According to the industry distribution chart, Nolato AB ranks #364 out of 697 companies in the Medical Devices & Instruments industry, placing it in the top 52.2%.
Is Nolato AB's Debt-to-Equity too high?
Nolato AB's current Debt-to-Equity is 0.00. Over the past 10 years, this metric has ranged from a low of 0.09 to a high of 0.51. Based on the distribution chart, Nolato AB ranks #364 out of 697 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Nolato AB has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Nolato AB's Debt-to-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Nolato AB ranks #364 out of 697 companies for Debt-to-Equity. This places Nolato AB in the lower half of its industry. The industry median Debt-to-Equity is 0.23. Historically, Nolato AB's own Debt-to-Equity has ranged from 0.09 to 0.51 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 697 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Nolato AB and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nolato AB's current Debt-to-Equity is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nolato AB stock overvalued right now?
Based on GuruFocus' analysis, Nolato AB (FRA:NBF) is currently considered Fairly Valued. The stock's GF Value™ is €4.64, compared to a current price of €4.68 — trading 0.9% above its estimated fair value. The current Debt-to-Equity is 0.00. Nolato AB's overall GF Score™ is 74/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Nolato AB (FRA:NBF), the current Debt-to-Equity is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nolato AB (FRA:NBF) Overvalued in 2026?
Based on GuruFocus' analysis, Nolato AB stock appears to be overvalued.
The current stock price of €4.68 is trading 0.9% above its estimated GF Value™ of €4.64.
GuruFocus considers Nolato AB to be Fairly Valued.
Key valuation signals for FRA:NBF:
Debt-to-Equity: 0.00
GF Value™: €4.64 vs. price of €4.68 (0.9% above fair value)
No single metric tells the full story. See the FRA:NBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nolato AB is a Swedish company that develops and manufactures plastic, silicone, and thermoplastic elastomer products. The firm's operations are organized into two segments: Medical Solutions and Engineered Solutions. The company generates the majority of its revenue from the Medical Solutions segment, which is engaged in the development and manufacture of complex product systems and components for medical devices, the pharmaceutical industry, and diagnostics. The Engineered Solutions design, development, industrialization, and manufacture of subsystems and ready-packaged products for a range of industries, including offerings within EMC and thermal solutions. Geographically, the firm generates key revenue from the Rest of Europe and the United States.
74GF Score
Get the complete analysis for FRA:NBF
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:NBF has been successfully added to your 
